Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam

Katsuhiro Kobayashi, Akihito Takeuchi, Makio Oka, Mari Akiyama, Yoko Ohtsuka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We report on an 18-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) (number of CAG repeats: 68) with progressive myoclonus epilepsy (PME), who showed a dramatic response to levetiracetam in terms of the intensity of myoclonus. He began to have convulsive seizures and myoclonus at 7 and 10. years of age, respectively, and his intelligence deteriorated from 12. years of age. EEG showed multifocal and diffuse spike-and-wave complexes. His convulsive seizures were suppressed from 13. years of age.At 17. years of age, the patient showed gradual intensification of erratic segmental positive myoclonus as well as frequent atonic falls that were probably attributable to negative myoclonus. Back averaging of EEG data revealed cortical discharges associated with positive myoclonus. Photosensitive myoclonic seizures were also observed. The administration of levetiracetam alleviated positive myoclonus and suppressed atonic falls, resulting in a remarkable improvement in the patient's quality of daily life.Reports on the efficacy of levetiracetam for myoclonus in DRPLA are still rare, though its effect on PME is known in the context of other neurological disorders. Thus levetiracetam should be subjected to clinical trials as a means of disabling myoclonus in DRPLA.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalBrain and Development
Volume34
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

etiracetam
Progressive Myoclonic Epilepsy
Myoclonus
Seizures
Electroencephalography
Nervous System Diseases
Intelligence

Keywords

  • Dentatorubral-pallidoluysian atrophy
  • Levetiracetam
  • Myoclonus
  • Negative myoclonus
  • Zonisamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Pediatrics, Perinatology, and Child Health

Cite this

Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam. / Kobayashi, Katsuhiro; Takeuchi, Akihito; Oka, Makio; Akiyama, Mari; Ohtsuka, Yoko.

In: Brain and Development, Vol. 34, No. 5, 05.2012, p. 368-371.

Research output: Contribution to journalArticle

Kobayashi, Katsuhiro ; Takeuchi, Akihito ; Oka, Makio ; Akiyama, Mari ; Ohtsuka, Yoko. / Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam. In: Brain and Development. 2012 ; Vol. 34, No. 5. pp. 368-371.
@article{3d3b39f8c0614ef7a248bacceb28993d,
title = "Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam",
abstract = "We report on an 18-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) (number of CAG repeats: 68) with progressive myoclonus epilepsy (PME), who showed a dramatic response to levetiracetam in terms of the intensity of myoclonus. He began to have convulsive seizures and myoclonus at 7 and 10. years of age, respectively, and his intelligence deteriorated from 12. years of age. EEG showed multifocal and diffuse spike-and-wave complexes. His convulsive seizures were suppressed from 13. years of age.At 17. years of age, the patient showed gradual intensification of erratic segmental positive myoclonus as well as frequent atonic falls that were probably attributable to negative myoclonus. Back averaging of EEG data revealed cortical discharges associated with positive myoclonus. Photosensitive myoclonic seizures were also observed. The administration of levetiracetam alleviated positive myoclonus and suppressed atonic falls, resulting in a remarkable improvement in the patient's quality of daily life.Reports on the efficacy of levetiracetam for myoclonus in DRPLA are still rare, though its effect on PME is known in the context of other neurological disorders. Thus levetiracetam should be subjected to clinical trials as a means of disabling myoclonus in DRPLA.",
keywords = "Dentatorubral-pallidoluysian atrophy, Levetiracetam, Myoclonus, Negative myoclonus, Zonisamide",
author = "Katsuhiro Kobayashi and Akihito Takeuchi and Makio Oka and Mari Akiyama and Yoko Ohtsuka",
year = "2012",
month = "5",
doi = "10.1016/j.braindev.2011.07.013",
language = "English",
volume = "34",
pages = "368--371",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam

AU - Kobayashi, Katsuhiro

AU - Takeuchi, Akihito

AU - Oka, Makio

AU - Akiyama, Mari

AU - Ohtsuka, Yoko

PY - 2012/5

Y1 - 2012/5

N2 - We report on an 18-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) (number of CAG repeats: 68) with progressive myoclonus epilepsy (PME), who showed a dramatic response to levetiracetam in terms of the intensity of myoclonus. He began to have convulsive seizures and myoclonus at 7 and 10. years of age, respectively, and his intelligence deteriorated from 12. years of age. EEG showed multifocal and diffuse spike-and-wave complexes. His convulsive seizures were suppressed from 13. years of age.At 17. years of age, the patient showed gradual intensification of erratic segmental positive myoclonus as well as frequent atonic falls that were probably attributable to negative myoclonus. Back averaging of EEG data revealed cortical discharges associated with positive myoclonus. Photosensitive myoclonic seizures were also observed. The administration of levetiracetam alleviated positive myoclonus and suppressed atonic falls, resulting in a remarkable improvement in the patient's quality of daily life.Reports on the efficacy of levetiracetam for myoclonus in DRPLA are still rare, though its effect on PME is known in the context of other neurological disorders. Thus levetiracetam should be subjected to clinical trials as a means of disabling myoclonus in DRPLA.

AB - We report on an 18-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) (number of CAG repeats: 68) with progressive myoclonus epilepsy (PME), who showed a dramatic response to levetiracetam in terms of the intensity of myoclonus. He began to have convulsive seizures and myoclonus at 7 and 10. years of age, respectively, and his intelligence deteriorated from 12. years of age. EEG showed multifocal and diffuse spike-and-wave complexes. His convulsive seizures were suppressed from 13. years of age.At 17. years of age, the patient showed gradual intensification of erratic segmental positive myoclonus as well as frequent atonic falls that were probably attributable to negative myoclonus. Back averaging of EEG data revealed cortical discharges associated with positive myoclonus. Photosensitive myoclonic seizures were also observed. The administration of levetiracetam alleviated positive myoclonus and suppressed atonic falls, resulting in a remarkable improvement in the patient's quality of daily life.Reports on the efficacy of levetiracetam for myoclonus in DRPLA are still rare, though its effect on PME is known in the context of other neurological disorders. Thus levetiracetam should be subjected to clinical trials as a means of disabling myoclonus in DRPLA.

KW - Dentatorubral-pallidoluysian atrophy

KW - Levetiracetam

KW - Myoclonus

KW - Negative myoclonus

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=84859924296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859924296&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2011.07.013

DO - 10.1016/j.braindev.2011.07.013

M3 - Article

C2 - 21889282

AN - SCOPUS:84859924296

VL - 34

SP - 368

EP - 371

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 5

ER -